RVMD FY 2025 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$17M

Operating Income

-$1.2B

Net Income

-$1.1B

EPS (Diluted)

$-5.95

Cash Flow

Operating Cash Flow

-$898M

Free Cash Flow

-$914M

Stock-Based Comp.

$118M

Balance Sheet

Total Assets

$2.4B

Total Liabilities

$723M

Stockholders' Equity

$1.6B

Cash & Equivalents

$384M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$17M	$0	—
Operating Income	-$1.2B	-$690M	-71.5%
Net Income	-$1.1B	-$600M	-88.5%